These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

738 related items for PubMed ID: 8104689

  • 1. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R.
    Cancer Res; 1993 Oct 15; 53(20):4960-70. PubMed ID: 8104689
    [Abstract] [Full Text] [Related]

  • 2. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA.
    Cancer Res; 1991 Jan 15; 51(2):556-67. PubMed ID: 1670762
    [Abstract] [Full Text] [Related]

  • 3. Quantitation of HER-2/neu oncoprotein overexpression in invasive breast cancer by image analysis: a study comparing fresh and paraffin-embedded material.
    van Diest PJ, Baak JP, Chin D, Theeuwes JW, Bacus SS.
    Anal Cell Pathol; 1991 Jul 15; 3(4):195-202. PubMed ID: 1679345
    [Abstract] [Full Text] [Related]

  • 4. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.
    Press MF, Hung G, Godolphin W, Slamon DJ.
    Cancer Res; 1994 May 15; 54(10):2771-7. PubMed ID: 7909495
    [Abstract] [Full Text] [Related]

  • 5. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
    Baak JP, Chin D, van Diest PJ, Ortiz R, Matze-Cok P, Bacus SS.
    Lab Invest; 1991 Feb 15; 64(2):215-23. PubMed ID: 1671789
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE, Pollice AA, Smith CA, Janocko LE, Sweeney L, Brown KA, Singh SG, Gu L, Yakulis R, Lucke JF.
    Clin Cancer Res; 1998 Apr 15; 4(4):913-28. PubMed ID: 9563885
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
    Pauletti G, Godolphin W, Press MF, Slamon DJ.
    Oncogene; 1996 Jul 04; 13(1):63-72. PubMed ID: 8700555
    [Abstract] [Full Text] [Related]

  • 10. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.
    Taiwan J Obstet Gynecol; 2007 Jun 04; 46(2):146-51. PubMed ID: 17638622
    [Abstract] [Full Text] [Related]

  • 11. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
    Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP.
    Anticancer Res; 1992 Jun 04; 12(2):419-25. PubMed ID: 1349794
    [Abstract] [Full Text] [Related]

  • 12. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H.
    Mod Pathol; 2002 Feb 04; 15(2):116-24. PubMed ID: 11850540
    [Abstract] [Full Text] [Related]

  • 13. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
    Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, Peles E, Ben-Baruch N, Farbstein H, Lupu R.
    Cancer Res; 1993 Nov 01; 53(21):5251-61. PubMed ID: 8106145
    [Abstract] [Full Text] [Related]

  • 14. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
    Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SA, Killander D, McGuire WL.
    Cancer Res; 1990 Jul 15; 50(14):4332-7. PubMed ID: 1973070
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HER-2/neu (c-erb-B2) gene and protein in breast cancer.
    Ross JS, Fletcher JA.
    Am J Clin Pathol; 1999 Jul 15; 112(1 Suppl 1):S53-67. PubMed ID: 10396301
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC.
    Oncogene; 1997 Feb 06; 14(5):561-8. PubMed ID: 9053854
    [Abstract] [Full Text] [Related]

  • 20. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
    Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH.
    Cancer Res; 1989 Apr 15; 49(8):2087-90. PubMed ID: 2564806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.